Infliximab induction ( DrugBank: Infliximab )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
97	潰瘍性大腸炎	2

97. 潰瘍性大腸炎

---

臨床試験数 : 2,630 /  薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04505410 (ClinicalTrials.gov)	November 18, 2020	5/8/2020	Second Line Induction Therapy and Healthy Diet for Patients With Ulcerative Colitis	A Randomized Control Study to Examine the Influence of a Healthy Diet on Moderate to Severe Ulcerative Colitis Patients Undergoing Second Line Induction With Biological Medications Tofacitinib, Ustekinumab or Vedolizumab	Ulcerative Colitis	Drug: Tofacitinib;Other: Fast Mimicking Diet;Drug: Ustekinumab induction;Drug: Infliximab induction	University of Miami	Pfizer	Recruiting	18 Years	N/A	All	76	Phase 3	United States
2	NCT02770040 (ClinicalTrials.gov)	July 18, 2016	9/5/2016	Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis	PREDICT UC: Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis	Ulcerative Colitis	Drug: Infliximab	Austin Health	University of Melbourne	Completed	18 Years	80 Years	All	138	Phase 4	Australia